What Does “Viable Bone Matrix” Mean? A Closer Look at ALLOCYTE® Plus
A viable bone matrix is a bone graft material that contains living cells alongside a bone-derived matrix. In this context, “viable” refers to cells that remain alive following processing, preservation, and preparation. Understanding that term helps healthcare professionals distinguish cellular bone graft products from materials evaluated primarily for their scaffold characteristics.
ALLOCYTE® Plus Advanced Viable Bone Matrix, offered by Sanara MedTech, is a cellular bone allograft containing viable, bone-derived progenitor cells. It uses a DMSO-free cryoprotectant to preserve the tissue during frozen storage.
For surgical teams, the important questions include what the graft contains, how viability is measured, and how handling requirements support its intended use. This guide explains those concepts and their relevance to product evaluation.
What Does “Viable” Tell Us?
Cell viability describes whether cells are alive under the conditions of a particular assessment. It provides information about the cellular component of a graft, but it does not independently predict a patient’s healing outcome.
Sanara’s ALLOCYTE Plus brochure reports an average of 1.5 million viable cells per cubic centimeter of allograft and average post-thaw cell viability exceeding 92%.
These figures describe reported product characteristics. They should not be interpreted as a percentage likelihood of successful fusion or bone healing.
When reviewing viability data, healthcare professionals can ask how the measurement was performed, when testing occurred, and which storage and preparation conditions applied. Those details help make the numbers meaningful.
Understanding the Bone Matrix Component
The ALLOCYTE Plus instructions describe a cryopreserved allograft made from cancellous bone chips and demineralized bone fibers. Its intended use is as a bone void filler.
The term “matrix” refers to the bone-derived material accompanying the cellular component. Evaluating a viable bone matrix therefore involves reviewing both the tissue structure and the preserved cells.
Surgical teams should consider whether the product’s composition and intended use fit the proposed application. A cellular graft’s features do not eliminate the need to assess the defect, surgical plan, patient factors, and current product instructions.
Three Terms Used in Bone Graft Discussions
Sanara’s brochure describes ALLOCYTE Plus through three concepts: an osteoconductive scaffold, the osteoinductive potential of demineralized cortical bone, and viable endogenous cells intended to support osteogenic healing processes.
These terms address different aspects of bone graft biology. Osteoconductivity concerns a framework for bone growth. Osteoinductivity concerns biological signals associated with bone formation. Osteogenesis concerns the formation of bone.
For product evaluation, reviewers should identify what evidence supports each stated characteristic. The presence of these concepts in a product description should not become a guarantee that every patient will achieve a particular outcome or healing timeline.
What Are Bone-Derived Progenitor Cells?
Sanara identifies the viable cellular component of ALLOCYTE Plus as bone-derived progenitor cells.
For healthcare professionals, that description raises useful questions about the preserved cell population. Which cells are identified? How are they characterized? What testing supports their viability and activity?
Precise terminology matters when explaining the product. A description of progenitor cells should not automatically be expanded into claims about unlimited differentiation or assured bone formation.
A focused review separates the identity of the cells, their measured condition, and evidence of clinical performance. Each contributes information, but each answers a different question.
Why Cryopreservation Matters
ALLOCYTE Plus is supplied as a cryopreserved graft. Its formulation includes a proprietary DMSO-free cryoprotectant, and Sanara states that rinsing or decanting the tissue before implantation is unnecessary.
DMSO stands for dimethyl sulfoxide. “DMSO-free” identifies a formulation characteristic; it does not mean that the product requires no preparation.
Facilities evaluating a cryopreserved graft should review the entire process from receipt through clinical use. Purchasing, storage, operating room preparation, and documentation all need to align with the supplied instructions.
Understanding those requirements helps teams assess practical fit alongside the product’s biological characteristics.
Thawing and the Working Window
The ALLOCYTE Plus instructions specify storage at −65°C or colder. They describe thawing the syringe in an ambient sterile saline bath for 10–15 minutes and require use within four hours of thawing, when appropriate, or disposal. The graft must not be refrozen.
These details make preparation timing an important part of workflow planning. Staff need to know when to retrieve the graft, who will prepare it, and how the thaw time will be communicated.
The instructions supplied with the actual product should guide preparation. An abbreviated brochure or educational article should not replace that procedure-specific reference.
Handling and Delivery Features
Sanara describes demineralized cortical fibers as providing conformable handling. ALLOCYTE Plus is packaged in an open-bore syringe that permits delivery directly from the syringe.
These features give surgical teams practical points to evaluate. Does the delivery format suit the anticipated access? What graft volume is needed? How will the material be handled within the planned procedure?
Handling convenience and clinical suitability should be reviewed together. A product can fit an operating room workflow while still requiring careful assessment of its intended application and patient-specific considerations.
Patient Selection and Tissue Safety
The package insert identifies contraindications including known sensitivities to listed processing agents, active systemic infection, and disorders creating unacceptable postoperative risk. It also explains that donor screening and processing cannot eliminate every possibility of infectious-agent transmission.
Healthcare professionals should review the complete current warnings, precautions, and contraindications before use.
The insert also requires patient records that support allograft traceability. Facilities should establish responsibility for linking graft identifiers with the recipient’s record and completing the accompanying tissue documentation.
These requirements are part of using donated human tissue and belong in staff education.
Evaluating ALLOCYTE Plus With Sanara MedTech
Understanding “viable bone matrix” begins with recognizing that the product contains both bone-derived material and preserved living cells. A thorough review then connects those characteristics with intended use, supporting evidence, preparation requirements, and the surgical team’s needs.
At Sanara MedTech, we help healthcare professionals access information about our surgical product portfolio.
